DEF 14A: Coeptis Therapeutics Holdings Seeks Stockholder Approval for Reverse Stock Split and $20 Million Equity Issuance

Coeptis Therapeutics Holdings is asking shareholders to approve a reverse stock split and the issuance of up to $20 million in securities at its upcoming annual meeting.

Summary

• Coeptis Therapeutics Holdings is holding its 2024 Annual Meeting of Stockholders virtually on December 18, 2024.
• The company is seeking stockholder approval for several key proposals, including the election of seven directors, ratification of the appointment of Astra Audit & Advisory, LLC as the independent auditor, and an amendment to the company's certificate of incorporation to allow for a reverse stock split.
• The proposed reverse stock split would be at a ratio between 1-for-3 and 1-for-40, with the exact ratio to be determined by the Board.
• Coeptis is also seeking approval to issue up to $20 million of securities in connection with a Standby Equity Purchase Agreement with Yorkville.
• Additionally, there will be a non-binding advisory vote on executive compensation.
• The record date for voting is November 1, 2024.
• As of the record date, there were 41,118,593 shares of common stock and 5,825 shares of Series A Preferred Stock outstanding, with the preferred stock representing a maximum of 7,619,898 votes on an as-converted basis.

Sentiment

Score: 4

Explanation: The document indicates financial challenges and the need for a reverse stock split to maintain listing, which is generally viewed negatively by investors. However, the company is taking steps to address these issues and secure additional funding.

Positives

• The Standby Equity Purchase Agreement with Yorkville provides a potential source of capital to bolster the company's financial position.
• The company is taking steps to regain compliance with Nasdaq listing requirements through the proposed reverse stock split.
• The company has a Scientific Advisory Board to provide guidance on product development.
• The company has a diverse board of directors with experience in various industries.

Negatives

• The reverse stock split could potentially decrease the liquidity of the company's common stock.
• The issuance of new shares under the Standby Equity Purchase Agreement will dilute existing shareholders' ownership.
• The company has previously received a deficiency letter from Nasdaq for not meeting the minimum bid price requirement.
• The company may not be able to maintain its Nasdaq listing even with the reverse stock split.

Risks

• The reverse stock split may not increase the price of the common stock over the long term.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.
• If the reverse stock split proposal is not approved, the company may face delisting from Nasdaq.
• The company may not be able to issue the full $20 million in securities under the Standby Equity Purchase Agreement if the proposal is not approved.
• The company's stock price may be affected by factors unrelated to the number of shares outstanding.

Future Outlook

The company intends to use the proceeds from the Standby Equity Purchase Agreement for working capital and general corporate purposes. The company is focused on regaining compliance with Nasdaq listing requirements and creating long-term value for stockholders.

Management Comments

• David Mehalick, Chief Executive Officer, encourages stockholders to vote their shares prior to the Annual Meeting.
• The Board of Directors recommends that stockholders vote FOR all proposals on the agenda for the Annual Meeting.

Industry Context

The company is operating in the biotechnology and pharmaceutical industry, which is characterized by high research and development costs and regulatory hurdles. The company's need for additional capital and its efforts to maintain its Nasdaq listing are common challenges faced by companies in this sector.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to stock price volatility.
• Reverse stock splits are a common strategy used by companies to regain compliance with minimum bid price requirements.
• Standby equity purchase agreements are a common financing tool for companies that need access to capital quickly.
• The company's board composition and committee structure are generally in line with industry standards for publicly traded companies.

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split and dilution from the equity issuance.
• Employees may be impacted by the company's financial stability and future prospects.
• Customers and suppliers may be impacted by the company's ability to continue operations.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on December 18, 2024.
• The Board will determine the exact ratio for the reverse stock split if the proposal is approved.
• The company will file the reverse stock split amendment with the Secretary of State of Delaware if approved.
• The company will potentially issue shares to Yorkville under the Standby Equity Purchase Agreement.

Key Dates

Keywords

reverse stock split, equity financing, Nasdaq listing, proxy statement, annual meeting, Astra Audit & Advisory, Standby Equity Purchase Agreement, Yorkville, executive compensation, board of directors